No benefit of CCP in COVID19 patients

Umesh Kumar Sapra Thank you

CCP is helpful in reducing the viral load during and only side effect of plasma transfusion is allergic reaction due to foreign protein which is manageable

Hi Dr Abdulsalam Al-Ani . I hope the following link could help:https://www.hematology.org/covid-19/covid-19-and-convalescent-plasma

See the following link that could help: https://europeanbloodalliance.eu/activities/convalescent-plasma-cpp/

Also, the following link that may help: https://bmjopenrespres.bmj.com/content/8/1/e001017

Dear Dr Dharmesh Chandra Sharma , totally agree with what you mentioned, but as you know the results of its effectiveness on the outcome showed contradictory (no consensus) results. However, most reports noticed effective signals if it is used early in the course of the disease with a high antibody titer (the later concurs with the FDA authorization).

Dear Dr Aref Wazwaz , thank you for the valuable articles, especially of ASH's journal (Hematology). However, I can't find the date of European Blood Alliance publication and the Uganda trial lacks the neutralizing antibody titration.

You are most welcome dear

Dr Abdulsalam Al-Ani .

Have a look at the following useful RG links for insights.

Article Convalescent plasma treatment of critically ill intensive ca...

Article Effectiveness of convalescent plasma therapy in severe COVID...

Article Treatment of COVID-19 Patients with Convalescent Plasma

Article Treatment of 5 Critically Ill Patients with COVID-19 with Co...

Article Treatment with convalescent plasma for COVID-19 patients in ...

Article Convalescent plasma therapy in patients with COVID-19

Dear Dr Arvind Singh and Sadanand Pandey

Dear Abdulsalam Al-Ani,

I totally agree with you .

In our area approximate results of 400 transfusions . It is effective in the stage of viremia to reduce viral load and reduces mortality.

Although there is controversy about its effectiveness still clinicians are demanding for CCP.

thanks

Dear Dharmesh Chandra Sharma ,

From our experience, we found no beneficial results on mortality!

However, we still in the process of learning from this devastating pandemic.

Thank you for your informative replies!

This is our newly published article;

Dear Colleagues, Dharmesh Chandra Sharma Sadanand Pandey

Aref Wazwaz Umesh Kumar Sapra Ameel F Alshawi

COVID-19 Convalescent Plasma was used widely in my country, Iraq. This is the 1st study conducted to assess its effectiveness among patients with comorbid conditions.

Article Association of chronic diseases with mortality among hospita...

Long term studies and even clinical trials conducted in multiple countries have not been able to reliably increase the mortality and morbidity of patients with COVID-19 treated with CCP.

Convalescent plasma can significantly reduce the 28-day mortality of severe or critical COVID-19 patients and the duration of mechanical ventilation.

Article The Effectiveness of Convalescent Plasma for the Treatment o...

Early transfusion (within 3 days of hospital admission) of high-titer plasma is associated with reduced risk of mortality among COVID-19 patients.

Article The Effect of Convalescent Plasma Therapy on COVID-19 Patien...

Convalescent plasma therapy may be given to people with COVID-19 who are in the hospital and are early in their illness or have a weakened immune system. Convalescent plasma therapy may help people recover from COVID-19 . It may lessen the severity or shorten the length of the disease Abdulsalam Al-Ani

Kindly see the following useful RG link: Article Covid-19 convalescent plasma therapy: Analyzing factors that...

Also check please the following useful RG link: Article COVID-19 Convalescent Plasma Treatment of Moderate and Sever...

The following RG link is also very good: Article Feasibility of collecting and processing of COVID-19 convale...

You are most welcome dear Abdulsalam Al-Ani

Wish you the best always

Thank you syed jaffar abbas Zaidi , I agree with you.

Thank you Aref Wazwaz Arvind Singh Shivam Maurya for your contributions

You are most welcome dear Abdulsalam Al-Ani

Wish you the best always

The following study conclude that among patients hospitalized with COVID-19 who are not receiving mechanical ventilation, transfusion of plasma with higher anti–SARS-CoV-2 IgG antibody levels is associated with a lower risk of death than transfusion of plasma with lower antibody levels. In addition, patients who received plasma within 3 days after the diagnosis of COVID-19 have a lower risk of death than those who received a transfusion later in the disease course.

Article Convalescent Plasma Antibody Levels and the Risk of Death fr...

The full-text of above article is available online

Among patients hospitalized with moderate-to-severe COVID-19, administration of convalescent plasma within 6 days of hospitalization in conjunction with standard of care treatment is associated with improved in-hospital mortality compared to standard of care treatment alone.

Article Early but not late convalescent plasma is associated with be...

Dear syed jaffar abbas Zaidi , if you read the article you can find the possible explanation for such high mortality and the reply of your kind comment; (Long term studies and even clinical trials conducted in multiple countries have not been able to reliably increase the mortality and morbidity of patients with COVID-19 treated with CCP.)

No benefit of methylene blue-treated convalescent plasma on viral load or the prevention of progression from mild to severe illness in outpatients with COVID-19.

For details, please have a look at this article link in The Lancet:

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00545-2/fulltext

Thank you Dear Muhammad Yousuf ,

You are right, the article mentioning;

Assessed 909 patients with confirmed COVID-19 for inclusion in the trial, 376 of whom were eligible and were randomly assigned to treatment;

Methylene blue-treated convalescent plasma did not prevent progression from mild to severe illness and did not reduce viral load in outpatients with COVID-19. Therefore, formal recommendations to support the use of convalescent plasma in outpatients with COVID-19 cannot be concluded.

Early treatment of newly diagnosed COVID-19 patients with plasma extracted from individuals who have recovered from the disease may reduce the risk of hospitalization.

https://www.news-medical.net/news/20220331/Convalescent-plasma-treatment-for-newly-diagnosed-COVID-19-patients-may-reduce-hospitalization-risk.aspx